Companies in the News

Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds

Biotechnology Veteran David Hung, M.D. Launches Stealth Start-Up Focusing on the Foremost Unmet Needs in Oncology Nuvation Bio's Proprietary Portfolio Includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing. The round was led, structured and syndicated by Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer

GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies

Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability Issued: London and San Francisco GlaxoSmithKline plc today announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients. The collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including GSK3377794, which targets the NY-ESO-1 antigen that is expressed across multiple cancer types. To date, two cell therapies have been approved for blood-borne cancers[1], but engineered T cells have not yet delivered strong clinical activity